Had a chance to contribute commentary on a study just published in JAMA on Sales for Prescription Drugs Marketed With and Without Orphan Drug Act Designation. Key points in🧵: MedPage Today Kristina Fiore #orphandrugs #raredisease medpagetoday.com/special-report…

I wrote about how #PatientsNotPatents (🐢🐢🐢John Green🐢🐢🐢/John Green, Partners In Health, MSF International, Stop TB Partnership, & many more!) successfully pushed Johnson & Johnson to allow generics of their TB drug bedaquiline. Read more in MedPage Today 👇 medpagetoday.com/special-report…

"What should infuriate people is that this is all public-sponsored research, right? So we're paying twice for it as taxpayers -- once when we invest in the research, because NIH grants are all funded by taxpayer dollars, and then we pay for it again when we buy it off the shelf."

Here is a Nature Biotech paper that I just published with an amazing Cambridge graduate student Victor van de Wiele. It shows how brand drug manufacturers have used "Patent Term Extension" from 2000-2018. nature.com/articles/s4158…

Reminder to sign up for our new monthly newsletter! Sharing our insights on the pharmaceutical industry—what we’re reading, writing, discussing Program On Regulation, Therapeutics, And Law.

Thanks Tami Luhby CNN for including me in this great piece about impact of Medicare price negotiation. Major savings for taxpayers and patients coming soon. cnn.com/2023/08/29/pol…

Here is a quote from my new JAMA paper with Rebecca Tushnet.

Here is one of two JAMA papers that I published this week with some amazing Harvard Medical School Folks. We show that FDA-regulated products suffer from "inequitable conduct" more frequently than any other industry.

Here is one of two JAMA papers that I published this week with a great researcher at Fresenius-Kabi. We show that some drug firms are using trade secrets and patents in a way that unjustly extends their monopoly power by over 10 years.

1/Thrilled to share this pre-print of my latest with S. Sean Tu & alex on the case for publicly owned & controlled pharmaceutical R&D: rb.gy/4cl5ki (forthcoming in The Journal of Law, Medicine & Ethics)

5/and if you ever get the chance to write or otherwise work with S. Sean Tu or alex, consider yourself very lucky. You guys make it easy!

📆 July 24 online: Prescription for Change: Reforming Patents to Lower Drug Costs bit.ly/4f2mPOs with our Canyon Brimhall, Wayne Brough, Tahir Amin Initiative for Medicines, Access & Knowledge, S. Sean Tu WVU College of Law

NEW in Nature Biotechnology: Analysis from S. Sean Tu & colleagues finds that 4% of 200 key drug patents had errors in their @USPTO calculated expiration dates, potentially resulting in hundreds of millions of dollars in added drug costs. nature.com/articles/s4158…

The cost of drug patent expiration date errors go.nature.com/3WvIuas

S. Sean Tu Program On Regulation, Therapeutics, And Law Dinis Cheian WVU College of Law .@USPTO software mistakes extend patent life for drugs and need to be fixed, researchers say #NBTintheNews via STAT statnews.com/pharmalot/2024…

A post on drug patents, exclusivity periods, and Medicare negotiation, and how pharma is trying to use the complexity to pull a fast one to grab $10 billion. A pharma company gets 20 years of patent protection on a drug, starting from date of filing. However, due to lengthy